Yaqiang Huang
Overview
Explore the profile of Yaqiang Huang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
51
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang Y, Zhu H, Liang Z, Wei W, Yang H, Wang Q, et al.
Biochim Biophys Acta Mol Basis Dis
. 2025 Feb;
1871(4):167722.
PMID: 39965532
Background: Prostate cancer (PCa) is a prevalent malignant tumor in men worldwide. Kinases play a key role in the development of multiple tumors. Nevertheless, the role of kinases in PCa...
2.
Xing Y, Huang Y, Tang Z, Lin Y, Zou Y, Huang Y, et al.
Front Immunol
. 2024 Aug;
15():1442027.
PMID: 39104527
Background: Mitochondrial damage contributes to apoptosis, oxidative stress, and inflammation, which collectively impact the immune system's function and the tumor microenvironment (TME). These processes, in turn, influence tumor cell growth,...
3.
Kong J, Zou Y, Zhou H, Huang Y, Lin Y, Fang S, et al.
Front Immunol
. 2024 Jun;
15:1404812.
PMID: 38938564
Background: The therapeutic effectiveness of immune checkpoint inhibitors (ICIs) in bladder cancer varies among individuals. Identifying reliable predictors of response to these therapies is crucial for optimizing patient outcomes. Methods:...
4.
Huang Y, Liu L, Gan Q, Shen Z, Yao Y, Liao C, et al.
Heliyon
. 2024 Apr;
10(7):e28160.
PMID: 38571632
Background: The prognostic significance of tumor size with adrenocortical carcinoma (ACC) patients has not yet been thoroughly evaluated. Our objective was to investigate the influence of tumor size on prognostic...
5.
Yang H, Wei W, Wang Q, Li L, Lin Q, Huang H, et al.
Urol Int
. 2024 Mar;
108(4):334-338.
PMID: 38537617
Introduction: The aim of this study was to explore the safety and feasibility of single-port nephroscopy combined with a needle electrode technique to unroof single dorsal simple renal cysts (SRCs)....
6.
Mai Z, Yuan R, Yan W, Zhou Y, Zhou Z, Ren M, et al.
Transl Cancer Res
. 2024 Mar;
13(2):651-660.
PMID: 38482427
Background: Without a pseudocapsule, prostate cancer is invasive in volume growth and has some regularity in spatial distribution. Our study aims to explore the specific origin location, invasive characteristics, and...
7.
Liang Y, Yin W, Cai Z, Luo H, Liu Q, Zhong C, et al.
Hum Genet
. 2023 Sep;
143(7):857-874.
PMID: 37758909
Nonmutational epigenetic reprogramming is a crucial mechanism contributing to the pronounced heterogeneity of prostate cancer (PCa). Among these mechanisms, N6-methyladenosine (m6A)-modified long non-coding RNAs (lncRNAs) have emerged as key players....
8.
Lu Y, Li B, Huang H, Leng Q, Wang Q, Zhong R, et al.
Front Oncol
. 2022 Dec;
12:1020317.
PMID: 36582803
Purpose: To investigate the predictive performance of the combined model by integrating clinical variables and radiomic features for the accurate detection of prostate cancer (PCa) in patients with prostate-specific antigen...
9.
Chen J, Huang Y, Tang Z, Li M, Ling X, Liao J, et al.
Front Cell Dev Biol
. 2021 Feb;
8:616332.
PMID: 33575255
Metformin is a classic type II diabetes drug which possesses anti-tumor properties for various cancers. However, different cancers do not respond to metformin with the same effectiveness or acquire resistance....
10.
Huang Y, Huang H, Han Z, Li W, Mai Z, Yuan R
J Nanosci Nanotechnol
. 2018 Nov;
19(4):1942-1950.
PMID: 30486934
To explore the molecular mechanism by which ginsenoside Rh2 (G-Rh2) inhibits prostate cancer by regulating vascular growth. Different concentrations of G-Rh2 with three prostate cancer cell lines (LNCaP, PC3 and...